同位素 ›› 2020, Vol. 33 ›› Issue (3): 186-198.DOI: 10.7538/tws.2019.youxian.009

• 综述 • 上一篇    

125I放射性粒子治疗癌症研究进展

黄金铭;于宁文   

  1. 中国原子能科学研究院 同位素研究所,北京102413
  • 出版日期:2020-06-20 发布日期:2020-09-12

Progress of Permanent Seed Implantation Using 125I-seeds for Cancer Therapy

HUANG Jinming;YU Ningwen   

  1. Department of Isotope, China Institute of Atomic Energy, Beijing 102413, China
  • Online:2020-06-20 Published:2020-09-12

摘要:

恶性肿瘤目前的治疗方法主要包括手术、放疗、化疗等。近年来,放射性核素碘[125I]粒子治疗肿瘤因其直接杀伤肿瘤病灶,在控制局部复发和转移方面具有一定优势。125I半衰期较长(T1/2=59.7 d),通过电子捕获释放低能γ射线(27 keV,特征X射线),适合用于近距离治疗肿瘤。125I 粒子可采用手术植入的方式埋植在肿瘤组织,对治疗肺癌、胰腺癌和前列腺癌等实体恶性肿瘤疗效显著, 治疗操作简单、损伤小,有较广泛应用前景。本文对125I放射性核素制备、125I放射性粒子制备及其临床肿瘤治疗情况及展望进行了综述。

关键词: 125I放射性粒子, 介入治疗, 恶性肿瘤, 近距离治疗

Abstract:

Malignant tumors are serious threat to human health. The way to treat cancer include surgery, radiotherapy and chemotherapy, etc. 125I is a radionuclide with a longer half-life (T1/2=59.7 d) and release of low-energy gamma rays (27 keV) by electron capture. 125I is suitable for brachy therapy in nuclear medicine and could be prepared as seed source widely used in clinic. 125I-seeds could be implanted into tumor tissue by surgical implantation. The therapeutic methods are simple and less invasive and have broad application prospects which show significant curative effect in lung cancer, pancreatic cancer, prostate cancer and other solid tumors. This paper reviews the research progress of the preparation of 125I and 125I-seeds, the 125I-seeds in treatment different types of tumors. The development trend for of 125I-seeds sources application is also been discussed.

Key words: 125I-seed, brachy therapy, malignant tumour, radiotherapy